A forum for researchers, students and applicants in the field of cyclodextrin technology
Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, announced encouraging headline results
In this study, antibody–supermolecule conjugates, consisting of a tumor-specific antibody and acid-labile polyrotaxane containing methylated b-cyclodextrin (Me-PRX), were designed to
Introduction: Antimicrobial resistance is one of the major scourges for healthcare worldwide, therefore novel investigational approaches are needed to potentiate and
Approval Based on the CANDOR and EQUULEUS Studies in Patients With Relapsed/Refractory Multiple Myeloma Amgen today announced the U.S. Food and
Transdermal drug delivery offers advantages over nonparenteral routes such as bypassing first-pass metabolism and facile administration. Mammalian skin, however, functions
This article reviews the controlled release of current anticancer drugs based on cyclodextrins as a “flexible switch”, and discusses the
2019 Nobel prize in Physiology or Medicine will be awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe and
The group of Prof. Mazzaglia published on a ternary nanoassembly (SAP) composed of nonionic amphiphilic β-cyclodextrins (amphiphilic CD) incorporating pheophorbide
Polymeric Nanoparticles as Promising Tool for Anti-cancer Therapeutics (edited by Prashant Kesharwani, Kishore Paknikar and Virendra Gajbhiye) and published by
